BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (NASDAQ:TRCA) today reported that earlier this week its partner IPSEN (Paris:IPN) submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Somatuline® Autogel® (lanreotide acetate) injection 60, 90 and 120 mg to treat patients with acromegaly. Tercica licensed from Ipsen the rights to develop and market Somatuline® Autogel® in the United States and Canada in a transaction that closed on October 13, 2006.
